Key facts
- This page summarizes Pascal Touchon's Form 4 filing for Atara Biotherapeutics, Inc. (ATRA).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Mar 2022, 18:02.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Award
Sale
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2022, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year.
Footnote F2
Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units.
Footnote F3
The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 1, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee.
Footnote F4
1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2022, subject to the reporting person's continuous service.